Abstract：
OBJECTIVE: This article discusses key considerations regarding ticagrelor\'s reported effect on heparin-induced thrombocytopenia functional assays, such as literature gaps and possible management strategies.
CONCLUSIONS: Limited data indicate that ticagrelor may induce false-negative results in functional assays used in the diagnosis of heparin-induced thrombocytopenia. False-negative functional assays for heparin-induced thrombocytopenia could have catastrophic consequences. The manufacturer labeling of ticagrelor now includes a warning for this potential drug-laboratory interaction. This article suggests areas that would benefit from further research and strategies in navigating this possible interaction.
CONCLUSIONS: Clinicians should exercise caution when evaluating functional assays for heparin-induced thrombocytopenia in patients receiving ticagrelor. This article offers suggestions for future areas of research and potential management strategies.
CONCLUSIONS: Limited data indicate that ticagrelor may induce false-negative results in functional assays used in the diagnosis of heparin-induced thrombocytopenia. False-negative functional assays for heparin-induced thrombocytopenia could have catastrophic consequences. The manufacturer labeling of ticagrelor now includes a warning for this potential drug-laboratory interaction. This article suggests areas that would benefit from further research and strategies in navigating this possible interaction.
CONCLUSIONS: Clinicians should exercise caution when evaluating functional assays for heparin-induced thrombocytopenia in patients receiving ticagrelor. This article offers suggestions for future areas of research and potential management strategies.
摘要：
结论：为了加快文章的发表，AJHP在接受后尽快在线发布手稿。接受的手稿经过同行评审和复制编辑，但在技术格式化和作者打样之前在线发布。这些手稿不是记录的最终版本，将在以后替换为最终文章（按照AJHP样式格式化并由作者证明）。
目的：本文讨论了关于替格瑞洛对肝素诱导的血小板减少症功能测定的报道效果的主要考虑因素，如文献空白和可能的管理策略。
结论：有限的数据表明，替格瑞洛可能在肝素诱导的血小板减少症的诊断中导致假阴性结果。肝素诱导的血小板减少症的假阴性功能测定可能会产生灾难性后果。替格瑞洛的制造商标签现在包括对这种潜在的药物-实验室相互作用的警告。本文提出了在导航这种可能的相互作用方面将从进一步的研究和策略中受益的领域。
结论：临床医生在评估替格瑞洛患者肝素诱导的血小板减少症的功能检测时，应谨慎行事。本文为未来的研究领域和潜在的管理策略提供了建议。
目的：本文讨论了关于替格瑞洛对肝素诱导的血小板减少症功能测定的报道效果的主要考虑因素，如文献空白和可能的管理策略。
结论：有限的数据表明，替格瑞洛可能在肝素诱导的血小板减少症的诊断中导致假阴性结果。肝素诱导的血小板减少症的假阴性功能测定可能会产生灾难性后果。替格瑞洛的制造商标签现在包括对这种潜在的药物-实验室相互作用的警告。本文提出了在导航这种可能的相互作用方面将从进一步的研究和策略中受益的领域。
结论：临床医生在评估替格瑞洛患者肝素诱导的血小板减少症的功能检测时，应谨慎行事。本文为未来的研究领域和潜在的管理策略提供了建议。
